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doesnot consider the costs of providing a service in this assessment.
TheUSPSTFrecognizes that clinicaldecisions involvemorecon-
siderations than evidence alone. Clinicians should understand the
evidence but individualize decision making to the specific patient
or situation. Similarly, the USPSTF notes that policy and coverage
decisions involve considerations in addition to theevidenceof clini-
cal benefits and harms.
Summary of Recommendation and Evidence
The USPSTF recommends against screening for chronic obstruc-




About 14% of US adults aged 40 to 79 years have COPD, and it is
the third leadingcauseofdeath in theUnitedStates.1,2 Personswith
severe COPD are often unable to participate in normal physical ac-
tivity due to deterioration of lung function.
Detection
Chronic obstructive pulmonary disease is defined as airflow limita-
tion that is not fully reversible. Chronic obstructive pulmonary dis-
ease is associated with an abnormal inflammatory response of the
lung to harmful particles or gases. Diagnosis is based on postbron-
chodilator spirometry, which detects fixed airway obstruction; a
forced expiratory volume in 1 second to forced vital capacity
(FEV1/FVC) ratio of less than0.70 is the current criterion for a posi-
tiveCOPDdiagnosis.PersonswithCOPDoften,butnotalways,have
symptoms such as dyspnea (difficulty breathing or shortness of
breath), chronic cough, and chronic sputum production. Patients
IMPORTANCE About 14% of US adults aged 40 to 79 years have chronic obstructive
pulmonary disease (COPD), and it is the third leading cause of death in the United States.
Persons with severe COPD are often unable to participate in normal physical activity due to
deterioration of lung function.
OBJECTIVE To update the 2008 US Preventive Services Task Force (USPSTF)
recommendation on screening for COPD in asymptomatic adults.
EVIDENCE REVIEW TheUSPSTF reviewed the evidence onwhether screening for COPD in
asymptomatic adults (thosewhodonot recognize or report respiratory symptoms) improves
health outcomes. TheUSPSTF reviewed thediagnostic accuracy of screening tools (including
prescreeningquestionnairesandspirometry);whether screening forCOPD improves thedelivery
anduptakeof targetedpreventiveservices, suchassmokingcessationor relevant immunizations;
and thepossible harmsof screening for and treatment ofmild tomoderate COPD.
FINDINGS Similar to 2008, the USPSTF did not find evidence that screening for COPD in
asymptomatic persons improves health-related quality of life, morbidity, ormortality. The
USPSTF determined that early detection of COPD, before the development of symptoms, does
not alter the course of the disease or improve patient outcomes. TheUSPSTF concludeswith
moderate certainty that screening for COPD in asymptomatic persons has no net benefit.
CONCLUSIONS AND RECOMMENDATION The USPSTF recommends against screening for COPD
in asymptomatic adults. (D recommendation)
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often have a history of exposure to risk factors such as cigarette
smokeor heating fuels or occupational exposure todusts or chemi-
cals. Although postbronchodilator spirometry is required to make
a definitive diagnosis, prescreening questionnaires can elicit cur-
rentsymptomsandpreviousexposures toharmfulparticlesorgases.
Benefits of Detection and Early Treatment
TheUSPSTF found inadequateevidence that screening forCOPD in
asymptomatic persons using questionnaires or spirometry im-
proves health outcomes.
Harms of Detection and Early Treatment
The USPSTF found inadequate evidence on the harms of screen-
ing. However, given the lack of benefit of early detection and
treatment, the opportunity cost associated with screening asymp-
tomatic persons may be large. The amount of time and effort
required to screen for COPD in asymptomatic persons (using
screening spirometry with or without prescreening question-
naires) is not trivial.
USPSTF Assessment
The USPSTF determined that early detection of COPD, before the
development of symptoms, does not alter the course of the dis-
easeor improvepatientoutcomes.TheUSPSTFconcludeswithmod-
erate certainty that screening for COPD in asymptomatic persons
hasnonetbenefit. Thus, screening is not recommended inpersons
who do not have symptoms suggestive of COPD. The USPSTF rec-
ommends against screening for COPD in asymptomatic adults.
Figure 1. US Preventive Services Task Force Grades and Levels of Certainty
What the USPSTF Grades Mean and Suggestions for Practice
Grade Definition
A The USPSTF recommends the service. There is high certainty that the net benefit is substantial. Offer or provide this service.
Suggestions for Practice
B The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or
there is moderate certainty that the net benefit is moderate to substantial.
Offer or provide this service.
C
The USPSTF recommends selectively offering or providing this service to individual patients
based on professional judgment and patient preferences. There is at least moderate certainty
that the net benefit is small.
Offer or provide this service for selected
patients depending on individual
circumstances.
D The USPSTF recommends against the service. There is moderate or high certainty that the service
has no net benefit or that the harms outweigh the benefits.
Discourage the use of this service.
I statement
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits
and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of
benefits and harms cannot be determined.
Read the Clinical Considerations section
of the USPSTF Recommendation
Statement. If the service is offered,
patients should understand the
uncertainty about the balance of benefits
and harms.
USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care
populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be
strongly affected by the results of future studies.
Moderate
The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate
is constrained by such factors as 
the number, size, or quality of individual studies.
inconsistency of findings across individual studies.
limited generalizability of findings to routine primary care practice.
lack of coherence in the chain of evidence.
As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large
enough to alter the conclusion.
The USPSTF defines certainty as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as
benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature
of the overall evidence available to assess the net benefit of a preventive service.
Low
The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of
the limited number or size of studies.
important flaws in study design or methods.
inconsistency of findings across individual studies.
gaps in the chain of evidence.
findings not generalizable to routine primary care practice.
lack of information on important health outcomes.
More information may allow estimation of effects on health outcomes.
USPSTF Recommendation: Screening for Chronic Obstructive Pulmonary Disease Special Communication Clinical Review& Education
jama.com (Reprinted) JAMA April 5, 2016 Volume 315, Number 13 1373
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
Clinical Considerations
Patient Population Under Consideration
This recommendation statement applies to asymptomatic adults
who do not recognize or report respiratory symptoms (Figure 2).
It does not apply to at-risk persons who present to clinicians with
symptoms such as chronic cough, sputumproduction, dyspnea, or
wheezing. It also does not apply to personswith a family history of
α1-antitrypsin deficiency.
Risk Assessment
Exposure to cigarette smoke or toxic fumes increases the risk for
COPD. Epidemiological studies have found that 15% to 50%
of smokers develop COPD.3 More than 70% of all COPD cases oc-
cur in current or former smokers. Occupational exposure to toxins,
dusts, or industrial chemicals contributes an estimated 15% of all
COPD cases. Environmental pollution, including wood smoke and
trafficpollutants, isalsoassociatedwith increasedrisk forCOPD.Non-
modifiable risk factors for COPD include history of asthma or child-
hood respiratory tract infections and α1-antitrypsin deficiency.
Screening Tests
Screening adults in primary care involves either risk assessment
via a formal prescreening questionnaire and, if positive, follow-up
with diagnostic spirometry testing or screening spirometry
administered without a bronchodilator and, if positive, follow-up
with diagnostic spirometry testing. Patients identified as high risk
by a prescreening questionnaire or screening spirometry are
referred for diagnostic spirometry testing. Diagnosis by spirom-
etry requires persistent airway obstruction after administration of
an inhaled bronchodilator, such as albuterol (ie, postbronchodila-
tor spirometry). Chronic obstructive pulmonary disease is diag-
nosed when the patient has a postbronchodilator FEV1/FVC ratio
of less than 0.70. Severity is defined by the percentage of pre-
dicted postbronchodilator FEV1; 80% or more is mild, 50% to
79% is moderate, 30% to 49% is severe, and less than 30% is
very severe.
Other Approaches to Prevention
Preventionof exposure to cigarette smokeandother toxic fumes is
the best way to prevent COPD. Interventions to prevent the initia-
tion of tobacco use are an effective way to prevent exposure to
cigarette smoke. Current smokers should receive smoking cessa-
tioncounselingandbeofferedbehavioralandpharmacological thera-
pies to stop smoking.
Useful Resources
TheUSPSTFrecommendsthatcliniciansaskall adults, includingpreg-
nantwomen, about tobacco use and provide tobacco cessation in-
terventions for those who use tobacco products. The USPSTF also
recommends that clinicians provide interventions, including edu-
cation or brief counseling, to prevent initiation of tobacco use in
school-aged children and adolescents. These recommendations
and their supporting evidence are available on theUSPSTFwebsite
(http://www.uspreventiveservicestaskforce.org).
Figure 2. Screening for Chronic Obstructive Pulmonary Disease: Clinical Summary
Population Asymptomatic adults who do not present with respiratory symptoms
Recommendation 







and Harms   
Other Relevant
USPSTF
Recommendations   
For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please
go to http://www.uspreventiveservicestaskforce.org.   
Risk factors include history of exposure to cigarette smoke or heating fuels; occupational exposure to toxins, dusts, or industrial
chemicals; exposure to environmental pollution, such as wood smoke and traffic pollutants; history of asthma or childhood
respiratory tract infections; and α1-antitrypsin deficiency.
Primary care screening involves either risk assessment via a formal prescreening questionnaire and, if positive, follow-up with
diagnostic spirometry testing or screening spirometry administered without a bronchodilator and, if positive, follow-up with
diagnostic spirometry testing.
Medications used to treat COPD include long-acting β-agonists, inhaled corticosteroids, long-acting anticholinergics, and
combination therapy with corticosteroids and long-acting β-agonists.
The USPSTF concludes with moderate certainty that screening for COPD in asymptomatic persons has no net benefit.
The USPSTF recommends that clinicians ask all adults, including pregnant women, about tobacco use and provide tobacco cessation
interventions for those who use tobacco products. The USPSTF also recommends that clinicians provide interventions, including
education or brief counseling, to prevent initiation of tobacco use in school-aged children and adolescents. These recommendations
are available on the USPSTF website (http://www.uspreventiveservicestaskforce.org).
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Other Considerations
Research Needs and Gaps
The USPSTF reviewed studies whose participants included former
and current smokers, butmany studies, including those that exam-
ined the accuracy of screening tools, did not report results sepa-
ratelybysmokingstatus (ie, currentvs formersmokers).Futurestud-
ies that stratify risk by smoking status could help identify different
risk groups that may benefit from screening. In addition, trials are
needed that assess theeffects of screeningamongcurrent andpre-
vious smokers inprimary careon long-termhealthoutcomes. Long-
termtrialsof treatmentofCOPDinscreen-detectedpatientsarealso
needed. Better treatment options for COPD and long-term epide-





About 13.7 million US adults are affected annually by COPD.4 As
lung function deteriorates over time, patients with COPD experi-
ence significant restrictions in their ability to work and participate
in other activities of daily living. In 2013, COPD was responsible
for about 10.3 million physician visits and 1.5 million emergency
department visits.4 Health care costs associated with COPD are
an estimated $32 billion per year.3 The prevalence of COPD and
its associated mortality have been rising among women, possibly
due to increasing smoking rates, environmental exposures, or
biological mechanisms that increase susceptibility to COPD.
Among different racial/ethnic groups, the prevalence of COPD is
highest among non-Hispanic white individuals (14.9%) and non-
Hispanic black individuals (12.8%).2,5
Scope of Review
Since the 2008 USPSTF recommendation, there is still no evi-
dence that screening for COPD in asymptomatic persons improves
health-related quality of life, morbidity, or mortality. The USPSTF
commissioned a systematic review to examine whether screening
for COPD improves the delivery and uptake of targeted preventive
services, such as smoking cessation or relevant immunizations. In
addition to the potential benefits of screening, theUSPSTF also ex-
amined the possible harms of screening for and treatment of mild
to moderate COPD. The diagnostic accuracy of screening tools
(including prescreening questionnaires and spirometry) was not
part of the previous systematic review but was evaluated in the
current review.3,6
Accuracy of Prescreening and Screening Tests
TheUSPSTF identified 3 externally validated questionnaires based
on risk factors, symptoms, or both: the COPD Diagnostic
Questionnaire,7,8 theLungFunctionQuestionnaire,9 and theCOPD
Population Screener.10 In addition, 3 other questionnaires are cur-
rently in development but have not yet been externally validated.3
TheCOPDDiagnosticQuestionnaire isan8-itemquestionnaire;using
a cutoff of greater than 16.5, it has a sensitivity of about 90% and
specificity of about40%for identifyingpersonswithCOPD in apri-
mary carepopulation.3 TheLungFunctionQuestionnaire is a5-item
questionnaire; using a cutoff of 18 or greater, it has a sensitivity of
approximately 88% and specificity of approximately 25% in a pri-
mary care population of current and former smokers.3 The COPD
Population Screener is a 5-itemquestionnaire; using a cutoff of 4or
greater, it has a sensitivity of 67% and specificity of 73% in a gen-
eral population in Japan.3
The USPSTF found 2 heterogeneous international studies of
screening with handheld peak flow meters that were not consid-
ered applicable to a US primary care population.3 Screening with
pulmonary function tests (without bronchodilators) was studied
in primary care populations in Australia and Sweden3 and yielded
sensitivity of about 50% and specificity of 90% for a cutoff of
less than 0.70. Another screening study conducted in Greece
evaluated postbronchodilator spirometry and yielded sensitivity
of 80% and specificity of 95% for the same cutoff.3 The USPSTF
found no pulmonary function screening studies conducted in the
United States.3
Effectiveness of Early Detection and Treatment
The USPSTF found no studies that directly assessed the effects of
screening for COPD in asymptomatic adults on morbidity, mortal-
ity, or health-related quality of life. TheUSPSTF also foundno stud-
ies that examined theeffectivenessof screeningon relevant immu-
nization rates. The USPSTF identified 5 studies that assessed the
effectsof screeningonsmokingcessation.11-15 These studiesprimar-
ily examined the incremental value of adding spirometry testing to
existing smoking cessation programs. One trial showed a statisti-
cally significant increase in smoking cessation rates between par-
ticipantswhoreceivedexplanationsof their spirometry resultsusing
“lung age” and thosewhodid not.11 The other 4 trials did not report
any significant differences in smoking abstinence rates.
The USPSTF examined the treatment efficacy of 4 classes of
medications used to treat COPD: long-acting β-agonists (LABAs),
inhaled corticosteroids, long-acting anticholinergics (tiotropium),
and combination therapy with corticosteroids and LABAs.3 No
treatment trials were conducted in asymptomatic or screen-
detected populations; all were conducted in populationswithmod-
erate COPD. Two studies of LABAs found no difference in all-cause
mortality but found decreased exacerbation of COPD symptoms in
the treatment vs control group in post hoc subanalysis. Decreased
exacerbation of COPD symptoms was reported for patients with
moderate to severe symptoms of COPD. However, rates of COPD
exacerbation were extremely low at baseline (<1 episode per year),
even among participants reporting symptoms. Six trials of inhaled
corticosteroids found decreased exacerbation of COPD symptoms
but no difference in all-cause mortality, dyspnea, or quality of life.
One trial of combination therapy with corticosteroids and LABAs
found decreased exacerbation of COPD symptoms but no differ-
ences in mortality or quality of life. Five trials of anticholinergics
found decreased exacerbation of COPD symptoms but insufficient
evidence on other outcomes. For all classes ofmedications, the one
consistent finding was that treatment decreases exacerbation of
COPD symptoms in persons with moderate COPD but has no con-
sistent effects on all-cause mortality, dyspnea, or quality of life.
There was insufficient evidence on the effects of treatment on
exercise capacity and functional status.
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Estimate ofMagnitude of Net Benefit
The potential harms of using prescreening questionnaires and
screening spirometry are false-positive and false-negative results.
TheUSPSTF foundno evidence to estimate the short- or long-term
harms of these screening tests. Potential harms of treatment in-
cludepneumoniawithuseofLABAsand inhaledcorticosteroidsand
decreased bone density and increased fractures with use of in-
haled corticosteroids. However, data were sparse, with few ad-
verse events, and therewerenodifferences between the interven-
tion and control groups.3
Because all of the treatment trials were conducted in persons
withmild tomoderate COPD, it is unclear how these results would
apply to asymptomatic populations. The potential treatment ben-
efit of decreased exacerbation of symptoms may not apply to
patients who report no symptoms to begin with. Given the lack of
potential benefits of treatment in asymptomatic persons and the
not-trivial work of screening, the USPSTF determined that there is
no net benefit of screening.
HowDoes the Evidence FitWith Biological Understanding?
Todate, treatment trialsofCOPDhavefoundmodest treatmentben-
efits in patientswithmild tomoderate COPD. Because themajority
of COPD cases result from exposure to cigarette smoke and other
toxic fumes, themost effectiveway topreventCOPD is to limit such
exposure. Persons with a history of exposure and symptoms such
as dyspnea, chronic cough, or sputumproduction should be evalu-
ated for the diagnosis of COPD.
Response to Public Comment
A draft version of this recommendation statement was posted for
public comment on the USPSTF website from August 18 to Sep-
tember 14, 2015. The USPSTF received requests for clarification
about whether high-risk groups, such as current smokers, were
included in the systematic review. In response, the USPSTF clari-
fied that both current and former smokers were included in the
studies reviewed. However, the lack of stratified results by smok-
ing status limits the USPSTF’s ability to make a separate recom-
mendation for screening in persons who are at higher risk for
COPD. The USPSTF recognizes that patients who have mild COPD
may underreport symptoms. The USPSTF encourages clinicians to
offer smoking cessation interventions to all patients who currently
smoke and to pursue active case-finding for COPD in patients with
risk factors, such as exposure to cigarette smoke or heating fuels,
occupational exposure to dusts or chemicals, or a family history of
α1-antitrypsin deficiency.
Update of Previous USPSTF Recommendation
This is an update of the 2008 USPSTF recommendation. In 2008,
the USPSTF recommended against screening for COPD with spi-
rometry in asymptomatic adults (D recommendation). This recom-
mendationwasbasedontheconclusionthatscreening forCOPDhad
no net benefit and large associated opportunity costs.
Recommendations of Others
In 2011, the American College of Physicians, American College of
Chest Physicians, American Thoracic Society, and European Respi-
ratory Society issued joint guidelines recommending that spirom-
etry be used to diagnose airflow obstruction in patientswith respi-
ratorysymptoms.16The jointpanel recommendedagainst screening
for COPDwith spirometry in asymptomatic patients, citing the lack
ofbenefit. Similarly, in2010, theUKNational Institute forHealthand
CareExcellencerecommendedagainstscreeningforCOPDinasymp-
tomatic patients.17 Recent guidelines from the Global Initiative for
Chronic Obstructive Lung Disease recommended case-finding in
symptomatic patients but did not recommend screening in asymp-
tomatic populations.18
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